secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuraxis, INC (NRXS)
CIK:        0001933567
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001493152-24-044545
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeurAxis Q3 revenue up 40% to $667K; operating loss narrows 45%; secures $5M investment
--------------------------------------------------------------------------------

- Revenue $667K, +40% YoY; unit sales +50%.
- Operating loss $1.7M, improved 45% from $3.0M; net loss $1.8M, improved 80%.
- Expanded insurance coverage to ~35M lives (from 4.5M); new FDA clearance for IB-Stim ages 8-21.
- Received CPT Category I code for PENFS effective Jan 1, 2026.
- Entered $5.0M investment agreement (closing mid-Nov), replacing prior $3.2M commitment; cash on hand $261K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/0001493152-24-044545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933567/000149315224044545/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer